Erlotinib: a new therapeutic approach for non-small cell lung cancer
P Bonomi - Expert opinion on investigational drugs, 2003 - Taylor & Francis
… Erlotinib (Tarceva™; OSI Pharmaceuticals, Genentech and Roche), a quinazoline derivative
… kinases that has been studied in clinical trials. In a Phase I study, mild diarrhoea and mild …
… kinases that has been studied in clinical trials. In a Phase I study, mild diarrhoea and mild …
Erlotinib for frontline treatment of advanced non–small cell lung cancer: a phase II study
G Giaccone, M Gallegos Ruiz, T Le Chevalier… - … Cancer Research, 2006 - AACR
… with advanced non–small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline
… The promising efficacy of erlotinib monotherapy in this study suggests that such therapy is a …
… The promising efficacy of erlotinib monotherapy in this study suggests that such therapy is a …
[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
… Similarly, results from the phase III BR.21 study indicated that erlotinib conferred a clinical
… erlotinib therapy. There were no unexpected safety findings relating to erlotinib in this study. …
… erlotinib therapy. There were no unexpected safety findings relating to erlotinib in this study. …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The lancet …, 2010 - thelancet.com
… Symptom improvement in lung cancer patients treated with erlotinib: quality of life
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …
[PDF][PDF] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - researchgate.net
… study examined the efficacy and safety of erlotinib combined with cisplatin and gemcitabine
for first-line treatment of advanced NSCLC. Overall, the erlotinib … 43 weeks for erlotinib plus …
for first-line treatment of advanced NSCLC. Overall, the erlotinib … 43 weeks for erlotinib plus …
[HTML][HTML] Erlotinib in lung cancer—molecular and clinical predictors of outcome
… The BR.21 study was a phase 3 trial of erlotinib involving patients who had had … small-cell
lung cancer. Patients were randomly assigned in a 2:1 ratio to receive 150 mg of erlotinib daily …
lung cancer. Patients were randomly assigned in a 2:1 ratio to receive 150 mg of erlotinib daily …
Retrospective study of erlotinib in patients with advanced squamous lung cancer
JS Tseng, TY Yang, KC Chen, KH Hsu, HY Chen… - Lung Cancer, 2012 - Elsevier
… The epidermal growth factor receptor (EGFR) mutation rate is low in lung SCC. The aim of
this study was to evaluate the status of erlotinib treatment and EGFR mutation in lung SCC …
this study was to evaluate the status of erlotinib treatment and EGFR mutation in lung SCC …
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
R Perez-Soler - Clinical cancer research, 2004 - AACR
… studies established a fixed daily oral dose of 150 mg as the recommended dose for
Phase II studies… with EGFR-positive non-small cell lung cancer after failure of platinum-containing …
Phase II studies… with EGFR-positive non-small cell lung cancer after failure of platinum-containing …
[HTML][HTML] Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer
T Kaburagi, H Satoh, K Hayashihara… - Oncology …, 2013 - spandidos-publications.com
… erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based observational
study. … Although 45.6% of the patients in this study received erlotinib as a fourth-line or …
study. … Although 45.6% of the patients in this study received erlotinib as a fourth-line or …
[HTML][HTML] A phase I study of erlotinib and hydroxychloroquine in advanced non–small-cell lung cancer
SB Goldberg, JG Supko, JW Neal, A Muzikansky… - Journal of Thoracic …, 2012 - Elsevier
… cell lung cancer cells and three representative clones that had been selected for resistance
either to gefitinib (GR3) or erlotinib (… B, Viability of parental PC9 cells and several GR or ER …
either to gefitinib (GR3) or erlotinib (… B, Viability of parental PC9 cells and several GR or ER …
相关搜索
- safety of erlotinib cell lung cancer
- role of erlotinib cell lung cancer
- review of erlotinib cell lung cancer
- effect of erlotinib cell lung cancer
- treatment with erlotinib cell lung cancer
- study of erlotinib cell lung cancer
- erlotinib monotherapy cell lung cancer
- non-small cell lung cancer treatment
- phase ii study cell lung cancer
- phase iii trial cell lung cancer
- clinical outcomes cell lung cancer
- egfr mutations cell lung cancers
- previously treated patients cell lung cancer
- combination with bortezomib cell lung cancer
- japanese patients cell lung cancer
- growth factor cell lung cancer